Globus Medical Inc. Class A Common Stock vs Valley National Bancorp Common Stock — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Valley National Bancorp Common Stock trades at $12.39 (market cap $6.92B). The key difference: Globus Medical Inc. Class A Common Stock is the larger of the two by market cap, and Valley National Bancorp Common Stock pays a 3.51% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Valley National Bancorp Common Stock for 6 Days on average.
| GMED | VLY | |
|---|---|---|
Market Cap | $10.25B | $6.92B |
Volume | 1,108,124 | 6,202,090 |
Sector | Health | Financials |
52-Week High | $96.82 | $15.19 |
52-Week Low | $58.33 | $9.72 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $9.76B | $9.43B |
Dividend Yield | — | 3.51% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Valley National Bancorp (VLY) trades at $12.53, down 0.87% with a bearish technical outlook. The stock shows strong fundamentals with a P/E of 10.61 and P/B of 0.91, indicating potential undervaluation. Recent earnings show mixed results with Q2 2026 missing estimates, but revenue growth remains solid at $2.2B for 2026. The company is actively expanding through acquisitions including Bluevine and Providence Financial to strengthen its deposit base and Chicago market presence.
Analyst consensus remains bullish with 62% buy ratings and a $16.50 price target, suggesting 32% upside potential. Key risks include integration challenges from recent acquisitions and higher operating expenses impacting margins. The upcoming Q3 2026 earnings report on October 22 will be crucial for validating growth trajectory amid current bearish technical signals.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →Valley National Bancorp is a financial holding company whose main subsidiary is Valley National Bank. It provides commercial, retail, trust, and investment services across several U.S. states.
Read more on VLY →